The classic story is this. A 58-year-old marketing director shaves Sunday morning and an electric shock fires through the right cheek into the upper teeth. It lasts four seconds. By Wednesday, taking a sip of cold water sets it off. By Friday, smiling at a coworker becomes dangerous. By the time the patient is in our office, they have lost six pounds because chewing on the right side is too risky to attempt.
That is trigeminal neuralgia. It is one of the most painful conditions in clinical medicine — the original “suicide disease” — and it is also one of the most treatable, provided the right diagnosis is made early and the right ladder is followed. The hard part is that trigeminal neuralgia is one of roughly a dozen distinct facial and cranial nerve pain syndromes that present in superficially similar ways but require very different treatment paths. Misdiagnosis is the rule, not the exception: most of our trigeminal neuralgia patients arrive after months of being told they have a “dental problem” or “atypical migraine.”
This page covers the differential, the diagnostic workup, and the procedural ladder we use at Modal Pain Management, 369 Lexington Avenue Floor 25 in Midtown Manhattan. Dr. Alex Movshis is dual board-certified in Anesthesiology and Pain Medicine and fellowship-trained in interventional pain medicine at the Icahn School of Medicine at Mount Sinai. Same-week new-patient consultations are routinely available.
When facial pain isn’t a dental problem — the diagnostic differential
The first job at the new-patient visit is to assign your pain to one of the following categories. Each has a different mechanism, a different diagnostic workup, and a different procedural answer. The category drives every downstream decision.
Classical trigeminal neuralgia (TGN, type 1). Brief — seconds to two minutes — electric, lancinating attacks confined to one or more divisions of the trigeminal nerve, almost always V2 (cheek and upper lip) or V3 (lower jaw). V1 (forehead, eye) is uncommon and should raise concern for shingles. Pain is triggered by light touch to a cutaneous “trigger zone” — shaving, brushing teeth, washing the face, a cold draft, chewing, speaking, even a kiss. Pain crosses the midline only rarely; bilateral TGN is a red flag for multiple sclerosis. Between attacks, the patient is pain-free.
Trigeminal neuralgia type 2 (TGN2) or trigeminal neuropathic pain. A constant aching or burning component layered onto the lancinating attacks. This pattern responds less reliably to microvascular decompression and is more likely to require a multimodal medication-plus-procedure approach.
Post-herpetic neuralgia (PHN) of the trigeminal distribution. Severe burning, allodynic pain in the dermatomal distribution of a healed shingles outbreak — most commonly the V1 (ophthalmic) distribution after herpes zoster ophthalmicus. The pain is not paroxysmal in the way TGN is — it is a near-constant burn punctuated by lancinating exacerbations. The history of a recent or remote zoster outbreak is the diagnostic anchor.
Occipital neuralgia (greater, lesser, or third occipital). Suboccipital pain that radiates over the back of the head toward the eye, sometimes reproduced by gentle tapping over the occipital nerve at the superior nuchal line (positive Tinel sign). Often confused with chronic migraine because it produces a similar headache-pattern symptom profile. The diagnostic block separates them in under five minutes — if anesthetizing the occipital nerve abolishes the headache, the diagnosis is occipital neuralgia, not migraine.
Glossopharyngeal neuralgia. Brief, sharp, lancinating pain in the throat, posterior tongue, tonsillar fossa, or ear triggered by swallowing, coughing, talking, or yawning. The clinical pearl: a small subset of patients have vagal-mediated syncope or bradycardia with attacks, so a cardiology workup is part of the evaluation.
Sphenopalatine ganglion–mediated pain. Pain in the upper face and forehead, often accompanied by autonomic features (lacrimation, conjunctival injection, ptosis, miosis, nasal congestion or rhinorrhea). In its severe paroxysmal form this is cluster headache; in milder forms it overlaps with chronic migraine and atypical facial pain. The diagnostic and therapeutic intervention is transnasal sphenopalatine ganglion block.
Persistent idiopathic facial pain (PIFP, formerly atypical facial pain). Constant, dull, aching, poorly localized facial pain that does not respect dermatomal boundaries and does not respond to carbamazepine. The diagnosis is one of exclusion. Treatment is multimodal and PIFP patients should be evaluated for psychiatric comorbidity in parallel with interventional care.
Temporomandibular disorder (TMD). Pain in the preauricular region, jaw, masseter, or temporalis with mechanical jaw symptoms (clicking, locking, restricted opening) and tenderness on palpation of the masseter and temporalis. This is sometimes presented as “facial nerve pain” but the right page for it is jaw pain & TMJ.
Post-traumatic trigeminal neuropathy. Persistent neuropathic pain in a trigeminal distribution after dental extraction, third molar surgery, dental implant placement, endodontic treatment, orthognathic surgery, or facial trauma. Mechanism is direct nerve injury; treatment overlaps with PHN.
Geniculate neuralgia and other rare cranial neuralgias. Deep ear pain triggered by stimulation of the external auditory canal. Rare. Requires ENT and pain medicine co-management.
The differential matters because the procedural answers are not interchangeable. A patient with classical TGN gets a different ladder than a patient with PIFP, and giving the wrong treatment to the wrong patient is the most common reason facial pain is “refractory” — it usually means a different pain generator is in play than the one that has been treated.
The diagnostic workup: what we order and why
The clinical history and physical examination do roughly 80 percent of the diagnostic work. The remaining 20 percent comes from targeted imaging and a diagnostic block.
MRI brain with trigeminal protocol. Every new TGN patient under age 60, every patient with bilateral or V1-dominant symptoms, every patient with sensory loss on cranial nerve examination, and every patient with atypical features gets an MRI. The protocol is thin-cut FIESTA/CISS (constructive interference in steady state) plus standard sequences, with attention to the cerebellopontine angle and the trigeminal cisternal segment. We are looking for three things: vascular compression of the trigeminal nerve at the root entry zone (the underlying mechanism of >85 percent of classical TGN), a cerebellopontine angle tumor (vestibular schwannoma, meningioma, epidermoid — uncommon but life-changing to find), and demyelinating plaques suggesting multiple sclerosis. For patients with persistent V1 pain after shingles, MRI also rules out herpes zoster meningoencephalitis.
Multiple sclerosis screen for trigeminal neuralgia in younger patients. TGN in a patient under 40, or bilateral TGN at any age, prompts neurology referral and a full MS workup including brain and cervical cord MRI with gadolinium.
Targeted laboratory workup. Diabetes is an independent risk factor for cranial neuropathies, so an A1C is part of the new-patient panel. For atypical or refractory facial pain we add ANA, Sjögren’s antibodies, ACE level (sarcoidosis), Lyme serology in appropriate exposure histories, and inflammatory markers.
Diagnostic divisional or peripheral nerve block. A diagnostic block is the single most efficient way to confirm the pain generator. For suspected TGN we perform an image-guided V2 or V3 division block. For suspected occipital neuralgia, an ultrasound-guided greater occipital nerve block. For suspected sphenopalatine ganglion involvement, a transnasal catheter SPG block. If the anesthetic abolishes the pain during the working window, the diagnosis is confirmed and the corresponding therapeutic procedure is set up. If the block fails to relieve the pain, the working diagnosis was wrong and the workup pivots.
The procedural ladder for trigeminal neuralgia
The first move is medical, the second is procedural, and the third is referral. The order matters and is based on randomized-trial and case-series evidence going back to the carbamazepine trials of the 1960s.
Step 1 — carbamazepine trial. Carbamazepine (Tegretol) is the first-line medication for classical TGN and has a near-pathognomonic response: most patients with true classical TGN get substantial relief within 48–72 hours at 200–400 mg twice daily. A clear positive response to carbamazepine is, in itself, strong supportive evidence for the diagnosis. Oxcarbazepine (Trileptal) is an alternative with a better tolerability profile. For patients who cannot tolerate carbamazepine — typical reasons include drowsiness, dizziness, hyponatremia, leukopenia, or rash — gabapentin, pregabalin, baclofen, or lamotrigine are reasonable second-line agents.
Step 2 — imaging-guided divisional block (V2 or V3). For patients with confirmed TGN who are not getting durable relief from medication, or who cannot tolerate medication side effects, the next step is a diagnostic-therapeutic divisional nerve block. We perform these under image guidance — ultrasound for peripheral branches (infraorbital for V2, mental and mandibular for V3) and fluoroscopy for foraminal approaches (foramen rotundum for V2, foramen ovale for V3). A small volume of local anesthetic plus low-dose corticosteroid is delivered onto or near the target nerve. Most patients get 4–12 weeks of relief; the block is repeatable, and patients who respond well are candidates for radiofrequency neurotomy.
Step 3 — radiofrequency neurotomy. For patients who have responded well to divisional blocks but are getting diminishing duration with each repeat, pulsed or conventional radiofrequency ablation of the affected trigeminal division is the next move. We typically choose pulsed RFA for cosmetic trigeminal divisions (V1, V2 distal) to avoid sensory loss in highly visible territory, and conventional thermal RFA for V3 mandibular targets where sensory loss is better tolerated. Duration of relief is typically 6–18 months and the procedure is safely repeatable. For patients with severe disease refractory to peripheral blocks and RFA, percutaneous Gasserian ganglion procedures — balloon compression, glycerol rhizotomy, or radiofrequency thermocoagulation — are performed by neurosurgery partners.
Step 4 — microvascular decompression (MVD) referral. For medically refractory classical TGN with imaging-confirmed neurovascular compression at the trigeminal root entry zone, the definitive treatment is microvascular decompression — a posterior fossa craniotomy in which the offending vessel is mobilized off the nerve and a Teflon sponge is placed between them. Published case series report initial pain freedom in 80–90 percent of carefully selected patients with 70 percent durability at 10 years. We coordinate referral to Mount Sinai and Weill Cornell neurosurgery for evaluation. MVD is most successful in younger patients with classical (type 1) TGN, clearly demonstrated arterial compression on FIESTA imaging, and no superimposed constant pain.
Step 5 — stereotactic radiosurgery referral (Gamma Knife, CyberKnife). For patients who are not surgical candidates — older patients, patients with multiple comorbidities, anticoagulated patients — stereotactic radiosurgery delivers a focused dose of radiation to the trigeminal root entry zone. Onset of relief is delayed (3–8 weeks) and the response is somewhat less durable than MVD, but the procedure is non-invasive and well-tolerated. Mount Sinai, NewYork-Presbyterian, and NYU Langone all offer trigeminal radiosurgery programs.
Treatment paths for the other facial nerve pain syndromes
Occipital neuralgia. First-line is medication (gabapentinoid plus topical lidocaine) and posture/ergonomic work, but most patients reach Modal because medication has failed. The fast diagnostic move is an ultrasound-guided occipital nerve block — if it abolishes the headache, the diagnosis is confirmed and the same procedure becomes therapeutic with corticosteroid added. Patients who get clear but diminishing-duration relief from repeat blocks are excellent candidates for pulsed radiofrequency ablation of the greater occipital nerve, which typically delivers 6–12 months of relief. For severe refractory cases, peripheral nerve stimulation of the greater occipital nerve is an option with a strong published track record.
Post-herpetic neuralgia. First-line is gabapentinoid plus topical agent (5% lidocaine patch, 8% capsaicin patch). For patients with refractory V1 PHN we offer ultrasound-guided supraorbital and supratrochlear nerve blocks (V1 distal branches) — typically with corticosteroid added — and pulsed RFA of the supraorbital nerve in patients who get clear short-duration relief from diagnostic blocks. Stellate ganglion block is an option for sympathetically-maintained components. Aggressive early intervention within the first 3 months after a shingles outbreak meaningfully reduces the risk of progressing to chronic PHN.
Sphenopalatine ganglion–mediated pain. Transnasal sphenopalatine ganglion block is performed in-office using a thin catheter passed along the floor of the nasal cavity to the posterior nasal wall, delivering local anesthetic to the SPG. The procedure takes five minutes, requires no needle, and produces fast diagnostic and therapeutic effect for cluster headache attacks, atypical facial pain with autonomic features, and V2 trigeminal pain. Patients who respond well are candidates for in-office SPG block series or for radiofrequency neurotomy of the ganglion.
Glossopharyngeal neuralgia. Carbamazepine is first-line as for TGN. For refractory cases, diagnostic-therapeutic glossopharyngeal nerve block at the styloid process is performed under image guidance. Patients with vagal-mediated cardiac symptoms during attacks require cardiology workup and may need temporary cardiac monitoring during the diagnostic block. Refractory cases are referred to neurosurgery for MVD of the glossopharyngeal nerve.
Persistent idiopathic facial pain. Mechanism is poorly understood and the response to interventional procedures is uneven. We use a structured trial of medication (tricyclic antidepressant or SNRI plus topical agent), evaluate for and treat comorbid TMD, screen for and refer comorbid depression and anxiety, and offer diagnostic blocks selectively to rule in or rule out a peripheral generator. Patients who get clear relief from a peripheral block become candidates for that target’s procedural ladder; patients who get no relief receive ongoing multimodal medical management rather than escalating procedural intervention.
What to expect at your first visit
The new-patient consultation is 45 minutes. Bring your full medication trial history with doses, your prior imaging on disc or via patient portal (we read your MRI ourselves during the visit), any neurology, ENT, or dental notes, and a brief written timeline of your pain — when it started, what triggers it, what makes it better, what has been tried. The timeline document is the single most useful artifact a new patient can bring.
The visit covers focused history, cranial nerve examination (corneal reflex, light touch in V1/V2/V3 distributions, masseter strength, sensory threshold testing), examination for occipital, TMJ, and cervical findings, and review of any prior imaging. The end product of the visit is a working diagnosis, a recommended next step (medication, imaging, or diagnostic block), a clear timeline for procedural scheduling if appropriate, and a written care plan you take with you.
If a procedure is indicated, it is almost always scheduled separately after benefits verification rather than performed the same day. Image-guided trigeminal, occipital, supraorbital, and supratrochlear blocks are performed in our procedure suite at 369 Lexington under local anesthesia, typically without IV sedation, with same-day discharge. Sphenopalatine ganglion blocks are performed in the clinic exam room. RFA procedures are performed under light sedation in the procedure suite.
When to come in versus when to go to the emergency department
A few features should send you to the emergency department rather than to a routine consultation: new severe headache that is the worst headache of your life (“thunderclap headache”), new neurological deficits (weakness, sensory loss, double vision, drooping eyelid, facial droop in a non-trigeminal pattern), new confusion or altered mental status, signs of meningitis (stiff neck, fever, photophobia), and shingles outbreak in the V1 distribution with eye involvement.
For everything else — established chronic facial pain that has not responded to dental, ENT, or neurology workup, suspected TGN that needs a diagnosis confirmed and a treatment plan, occipital neuralgia masquerading as migraine, refractory PHN — the appropriate cadence is same-week routine consultation. Most insurance plans, including most commercial PPOs, cover both consultation and image-guided procedures with prior authorization that we handle on your behalf.
To schedule, book online or call (646) 290-6660. Dr. Movshis sees every patient personally at every visit — initial consultation through follow-up.